Last 12 months
Inside the activity.
10 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 9 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2016 Filed Jan 18, 2017 15:28 UTC |
Huh HoyoungDirector · Chairman, Scientific Adv. Bd.
|
GrantStock Option (right to buy) · Derivative | 4,000,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001140361-17-002117 · doc1.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · Chairman, Scientific Adv. Bd. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2026-10-31 F1 · shares: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. F2 · derivative.exercise_date: The option vests in forty-eight equal installments beginning on the date so indicated and every month thereafter, such grant vested in full at 4 years. F1 · derivative.underlying_shares: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. F1 · balance_after: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.